InflaRx (IFRX) Competitors $0.91 +0.02 (+1.73%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.94 +0.03 (+2.79%) As of 08/22/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IFRX vs. CRGX, HRTX, OGI, PRQR, AVTE, SOPH, LYEL, MNPR, GNFT, and IPHAShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include CARGO Therapeutics (CRGX), Heron Therapeutics (HRTX), Organigram Global (OGI), ProQR Therapeutics (PRQR), Aerovate Therapeutics (AVTE), SOPHiA GENETICS (SOPH), Lyell Immunopharma (LYEL), Monopar Therapeutics (MNPR), GENFIT (GNFT), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. Its Competitors CARGO Therapeutics Heron Therapeutics Organigram Global ProQR Therapeutics Aerovate Therapeutics SOPHiA GENETICS Lyell Immunopharma Monopar Therapeutics GENFIT Innate Pharma InflaRx (NASDAQ:IFRX) and CARGO Therapeutics (NASDAQ:CRGX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment. Do analysts rate IFRX or CRGX? InflaRx currently has a consensus price target of $6.60, indicating a potential upside of 622.50%. CARGO Therapeutics has a consensus price target of $15.40, indicating a potential upside of 244.52%. Given InflaRx's stronger consensus rating and higher possible upside, analysts clearly believe InflaRx is more favorable than CARGO Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00CARGO Therapeutics 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86 Which has more volatility & risk, IFRX or CRGX? InflaRx has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, CARGO Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Is IFRX or CRGX more profitable? CARGO Therapeutics' return on equity of -43.21% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets InflaRxN/A -71.76% -57.68% CARGO Therapeutics N/A -43.21%-37.26% Which has stronger valuation & earnings, IFRX or CRGX? InflaRx has higher revenue and earnings than CARGO Therapeutics. InflaRx is trading at a lower price-to-earnings ratio than CARGO Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInflaRx$180K340.68-$49.85M-$0.80-1.14CARGO TherapeuticsN/AN/A-$167.50M-$4.64-0.96 Does the media refer more to IFRX or CRGX? In the previous week, CARGO Therapeutics had 1 more articles in the media than InflaRx. MarketBeat recorded 3 mentions for CARGO Therapeutics and 2 mentions for InflaRx. CARGO Therapeutics' average media sentiment score of 0.38 beat InflaRx's score of 0.00 indicating that CARGO Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CARGO Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in IFRX or CRGX? 42.4% of InflaRx shares are owned by institutional investors. Comparatively, 93.2% of CARGO Therapeutics shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 2.9% of CARGO Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryInflaRx beats CARGO Therapeutics on 8 of the 14 factors compared between the two stocks. Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.29M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-1.1420.8831.1026.04Price / Sales340.68349.56435.26103.29Price / CashN/A43.1937.7358.48Price / Book0.958.129.536.61Net Income-$49.85M-$54.72M$3.26B$265.56M7 Day Performance5.86%2.63%2.10%1.95%1 Month Performance6.37%2.78%2.82%-0.37%1 Year Performance-42.18%11.01%30.56%19.02% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx2.5698 of 5 stars$0.91+1.7%$6.60+622.5%-39.5%$60.29M$180K-1.1460News CoverageHigh Trading VolumeCRGXCARGO Therapeutics2.0832 of 5 stars$4.46flat$15.40+245.3%N/A$215.71MN/A-0.96116News CoverageAnalyst UpgradeHRTXHeron Therapeutics4.2078 of 5 stars$1.35-3.6%$4.50+233.3%-25.1%$214.61M$144.29M-67.50300Positive NewsOGIOrganigram Global0.3952 of 5 stars$1.56-2.5%N/A-17.5%$214.44M$117.47M31.21860High Trading VolumePRQRProQR Therapeutics2.6847 of 5 stars$2.02flat$8.00+296.0%+6.6%$212.53M$20.46M-4.39180AVTEAerovate TherapeuticsN/A$7.33-0.8%N/A-88.5%$212.46MN/A-2.4520Gap UpHigh Trading VolumeSOPHSOPHiA GENETICS2.9641 of 5 stars$3.28+5.5%$8.00+143.9%+2.0%$210.17M$65.17M-7.45520Positive NewsLYELLyell Immunopharma3.7546 of 5 stars$10.76-0.6%$15.00+39.4%-62.9%$208.06M$60K-0.44270Positive NewsMNPRMonopar Therapeutics2.8921 of 5 stars$35.86+7.0%$60.00+67.3%+1,061.6%$206.76MN/A-10.7710GNFTGENFIT2.186 of 5 stars$4.11+0.7%$13.00+216.3%-2.8%$203.91M$76.77M0.00120News CoverageAnalyst ForecastAnalyst RevisionIPHAInnate Pharma1.721 of 5 stars$2.18-1.4%$11.00+404.6%-0.4%$203.73M$21.77M0.00220Short Interest ↑Gap Up Related Companies and Tools Related Companies CARGO Therapeutics Competitors Heron Therapeutics Competitors Organigram Global Competitors ProQR Therapeutics Competitors Aerovate Therapeutics Competitors SOPHiA GENETICS Competitors Lyell Immunopharma Competitors Monopar Therapeutics Competitors GENFIT Competitors Innate Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IFRX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.